At a glance
FDA approval FDA-approved 38 applications
Randomized controlled trials 307 of 5,883 publications on PubMed
Registered clinical trials 127 16 active
Adverse event reports 10,281 7,376 classified as serious
- Desmopressin is an FDA-approved drug, marketed as Ddavp, Desmopressin, Desmoda (first approval: March 30, 1984).
- PubMed lists 5,883 publications mentioning it, including 307 randomized controlled trials and 787 animal-only studies.
- ClinicalTrials.gov lists 127 registered studies testing it (16 active).
- FDA's adverse event system (FAERS) holds 10,281 reports mentioning it; 7,376 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
| NDA017922 | DDAVP, DDAVP (NEEDS NO REFRIGERATION) | Approved, discontinued | February 21, 1978 | FERRING PHARMS INC |
| NDA018938 | DDAVP | Approved, marketed | March 30, 1984 | J MOLNER |
| NDA019776 | CONCENTRAID | Approved, discontinued | December 26, 1990 | FERRING |
| NDA020355 | STIMATE, STIMATE (NEEDS NO REFRIGERATION) | Approved, discontinued | March 7, 1994 | FERRING PHARMS INC |
| NDA019955 | DDAVP | Approved, marketed | September 6, 1995 | FERRING PHARMS INC |
| ANDA074888 | DESMOPRESSIN ACETATE | Approved, marketed | October 15, 1997 | MEITHEAL |
| ANDA074830 | DESMOPRESSIN ACETATE | Approved, discontinued | January 25, 1999 | BAUSCH |
| ANDA074574 | DESMOPRESSIN ACETATE PRESERVATIVE FREE | Approved, discontinued | February 18, 2000 | BEDFORD |
| ANDA074575 | DESMOPRESSIN ACETATE | Approved, discontinued | February 18, 2000 | BEDFORD |
| ANDA075220 | DESMOPRESSIN ACETATE | Approved, discontinued | August 28, 2000 | HOSPIRA |
| NDA021333 | MINIRIN | Approved, discontinued | September 16, 2002 | FERRING |
| ANDA076703 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | Approved, marketed | January 27, 2005 | APOTEX |
| ANDA076470 | DESMOPRESSIN ACETATE | Approved, discontinued | July 1, 2005 | ACTAVIS LABS FL INC |
| ANDA077122 | DESMOPRESSIN ACETATE | Approved, discontinued | January 25, 2006 | IMPAX LABS INC |
| ANDA077414 | DESMOPRESSIN ACETATE | Approved, marketed | March 7, 2006 | APOTEX |
| NDA021795 | DESMOPRESSIN ACETATE | Approved, discontinued | May 8, 2008 | FERRING |
| ANDA077212 | DESMOPRESSIN ACETATE | Approved, discontinued | April 12, 2012 | SUN PHARM INDS |
| ANDA091280 | DESMOPRESSIN ACETATE | Approved, discontinued | January 25, 2013 | SUN PHARM INDS LTD |
| ANDA078271 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | Approved, discontinued | December 23, 2013 | SUN PHARM |
| ANDA200653 | DESMOPRESSIN ACETATE | Approved, discontinued | June 27, 2014 | NATCO PHARMA USA |
| ANDA201831 | DESMOPRESSIN ACETATE | Approved, discontinued | May 28, 2015 | GLENMARK PHARMS LTD |
| NDA201656 | NOCTIVA | Approved, discontinued | March 3, 2017 | ACERUS PHARMS |
| ANDA207880 | DESMOPRESSIN ACETATE | Approved, marketed | May 26, 2017 | HERITAGE PHARMA |
| ANDA204695 | DESMOPRESSIN ACETATE | Approved, marketed | August 22, 2017 | SAGENT PHARMS INC |
| ANDA204751 | DESMOPRESSIN ACETATE | Approved, marketed | August 22, 2017 | SAGENT PHARMS INC |
| ANDA091345 | DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION) | Approved, marketed | October 3, 2017 | ZYDUS PHARMS |
| NDA022517 | NOCDURNA | Approved, discontinued | June 21, 2018 | FERRING PHARMS INC |
| ANDA210371 | DESMOPRESSIN ACETATE | Approved, marketed | January 28, 2019 | ABHAI LLC |
| ANDA091374 | DESMOPRESSIN ACETATE | Approved, discontinued | February 14, 2019 | AM REGENT |
| ANDA208357 | DESMOPRESSIN ACETATE | Approved, marketed | June 6, 2019 | NOVAST LABS |
| ANDA210218 | DESMOPRESSIN ACETATE | Approved, marketed | February 14, 2020 | UBI |
| ANDA210223 | DESMOPRESSIN ACETATE | Approved, marketed | September 17, 2020 | UBI |
| ANDA215961 | DESMOPRESSIN ACETATE | Approved, marketed | August 19, 2022 | DR REDDYS |
| ANDA216922 | DESMOPRESSIN ACETATE | Approved, marketed | November 16, 2022 | GLAND |
| ANDA216904 | DESMOPRESSIN ACETATE | Approved, marketed | March 20, 2023 | GLAND |
| ANDA213095 | DESMOPRESSIN ACETATE | Approved, marketed | March 21, 2024 | AUROBINDO PHARMA |
| NDA219873 | DESMODA | Approved, marketed | February 25, 2026 | ETON |
| ANDA219981 | DESMOPRESSIN ACETATE | Approved, marketed | February 27, 2026 | CAPLIN |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
- All publications 5,883
- Human (MeSH) 4,343
- Animal only 787
- Clinical trials 548
- Randomized controlled trials 307
- Systematic reviews & meta-analyses 134
- Case reports 1,202
- Retracted 0
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 127
- Active
- 16
- With posted results
- 19
| Study | Status | Phase | Start |
| FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps NCT07855315 Services Institute of Medical Sciences, Pakistan | Not yet recruiting | N/A | October 15, 2026 |
| Bedtime Device Restriction and Desmopressin in PMNE. NCT07776977 Al-Azhar University | Recruiting | N/A | August 20, 2026 |
| DDAVP Effect by TEG6 in Cardiac Surgery NCT07179991 London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | — | August 1, 2026 |
| Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors NCT07712328 Zhaoyun Zhang | Enrolling by invitation | Phase 4 | June 2, 2026 |
| DDAVP for Pituitary Adenoma NCT04569591 National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | N/A | March 9, 2026 |
| Transfusion Reduction in High-Bleeding-Risk Cardiac Surgery With Desmopressin NCT07012837 Imam Abdulrahman Bin Faisal University | Not yet recruiting | Phase 3 | Jul 2025 |
| Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial NCT06337838 Hamilton Health Sciences Corporation | Recruiting | Phase 3 | June 9, 2025 |
| Effectiveness of Pelvic Floor Muscle Rehabilitation Combined With Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis NCT06883851 Bahçeşehir University | Recruiting | N/A | March 11, 2025 |
| Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia NCT06020495 Assistance Publique - Hôpitaux de Paris | Recruiting | Phase 3 | December 17, 2024 |
| Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome NCT06635629 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | Phase 2 | December 12, 2024 |
Show 40 more studies
| Study | Status | Phase | Start |
| Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE NCT07199894 Mansoura University | Recruiting | Phase 3 | December 1, 2024 |
| Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies NCT06622187 Hospital de Clinicas de Porto Alegre | Enrolling by invitation | Phase 4 | August 14, 2024 |
| International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia NCT07576036 Rochester General Hospital | Enrolling by invitation | — | November 1, 2023 |
| Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin NCT05467033 Medical University of Bialystok | Recruiting | Phase 3 | September 1, 2022 |
| Uroflowmetry and Nocturnal Enuresis NCT07028645 Furkan Adem Canbaz | Active, not recruiting | — | August 20, 2022 |
| Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT NCT06962202 Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | — | August 15, 2022 |
| Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency NCT07292753 Ain Shams University | Completed | N/A | December 15, 2024 |
| Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis NCT06771128 Menoufia University | Completed | N/A | November 1, 2024 |
| Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volume and Anti-inflammatory Effect of Spinal Endoscopic Lumbar Fusion NCT06255366 Chengdu University of Traditional Chinese Medicine | Unknown status | Phase 4 | March 28, 2024 |
| Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD NCT06277336 University Hospital, Basel, Switzerland | Completed | N/A | March 1, 2024 |
| Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis NCT06285006 Al-Azhar University | Unknown status | N/A | February 23, 2024 |
| Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis NCT06772584 Menoufia University | Completed | N/A | January 1, 2024 |
| Adding Desmopressin to Tamsulosin for Treatment of BPH NCT05945420 Mansoura University | Unknown status | Phase 4 | July 20, 2023 |
| Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis. NCT06185361 Fayoum University Hospital | Unknown status | N/A | December 1, 2022 |
| Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis NCT05617664 Benha University | Unknown status | N/A | November 23, 2022 |
| Intravenous Tranexamic Acid and Intramyometrial Desmopressin Effect on Blood Loss During Laparoscopic Myomectomy. NCT05517590 Acibadem University | Completed | N/A | September 1, 2022 |
| Nasal Desmopressin Versus Topical Epinephrine in Endonasal Dacryocystorhinostomy NCT05507476 Zagazig University | Completed | N/A | September 1, 2022 |
| Nasal Desmopressin Versus Oral Bisoprolol for Controlling Bleeding During Endoscopic Sinus Surgery NCT05430048 Zagazig University | Completed | Phase 2 | July 1, 2022 |
| Effect of Laser Acupuncture for Treating Monosymptomatic Nocturnal Enuresis in Adolescent Females NCT05399173 Cairo University | Unknown status | N/A | June 2, 2022 |
| Decline in Renal Concentration Ability in Lithium Treated Patients NCT05307042 Radboud University Medical Center | Unknown status | — | May 2022 |
| Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A NCT06020456 Groupe Maladies hémorragiques de Bretagne | Completed | — | January 1, 2022 |
| NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden NCT04740645 Ferring Pharmaceuticals | Completed | — | July 13, 2021 |
| Validation of Capillary Serum Sodium Levels NCT05414279 University Hospital, Ghent | Completed | N/A | April 30, 2021 |
| the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock NCT04586790 Ahmed talaat ahmed aly | Unknown status | Phase 2 | October 15, 2020 |
| Desmopressin for Bedwetting in Children With SCD NCT04420585 Montefiore Medical Center Results posted | Terminated | Phase 4 | July 7, 2020 |
| Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A NCT05628558 Groupe Maladies hémorragiques de Bretagne | Unknown status | — | July 1, 2020 |
| Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia) NCT04329975 Ferring Pharmaceuticals | Completed | — | May 19, 2020 |
| Posterior Tibial Nerve Stimulation Vs Desmopressin In Children With Primary Monosymptomatic Nocturnal Enuresis NCT04545931 Cairo University | Unknown status | Phase 4 | March 15, 2020 |
| A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers NCT04103034 Band Therapeutics Results posted | Completed | Phase 1 | October 7, 2019 |
| Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer NCT04113005 Sunnybrook Health Sciences Centre | Unknown status | Early phase 1 | October 1, 2019 |
| Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage NCT03696121 University of Nottingham | Completed | Phase 2 | April 1, 2019 |
| A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 NCT03847207 Nxera Pharma UK Limited | Completed | Phase 1 | January 23, 2019 |
| Study on Chinese and Western Medicine in MNE Children NCT03733873 Children's Hospital of Fudan University | Completed | N/A | September 1, 2018 |
| To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors NCT03676361 University of Kansas Medical Center | Withdrawn | Phase 4 | August 29, 2018 |
| Exercise Versus DDAVP in Patients With Mild Hemophilia A NCT03379974 Nationwide Children's Hospital | Completed | Phase 4 | July 31, 2018 |
| The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings. NCT03389412 University of Aarhus | Completed | Phase 4 | October 1, 2017 |
| Prophylactic Desmopressin Before Native Kidney Biopsy in Severe Renal Impairment NCT07840313 Sindh Institute of Urology and Transplantation | Completed | N/A | August 1, 2017 |
| A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults NCT03201419 Ferring Pharmaceuticals Results posted | Completed | Phase 2 | July 27, 2017 |
| DDAVP vs. Exercise in Patients With Mild Hemophilia A NCT03136003 The Hospital for Sick Children | Unknown status | Phase 4 | July 4, 2017 |
| Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast. NCT03054662 Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | N/A | January 16, 2017 |
All 127 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 10,281
- Serious
- 7,376
- With death outcome
- 736
Most reported reactions
- Hyponatraemia 1,118
- Drug ineffective 807
- Headache 583
- Off label use 559
- Nausea 444
- Vomiting 408
- Fatigue 397
- Dizziness 332
- Fall 287
- Diarrhoea 286
- Drug interaction 286
- Malaise 264
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Boxed warning Desmopressin Acetate · August 27, 2026
Original FDA text (English) WARNING: HYPONATREMIA Desmopressin acetate can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death [see Warnings and Precautions ( 5.1 )] . Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. Ensure the serum sodium concentration is normal before starting or resuming desmopressin acetate. Measure serum sodium within 7 days and approximately 1 month after initiating therapy, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. If hyponatremia occurs, desmopressin acetate may need to be temporarily or permanently discontinued [see Warnings and Precautions ( 5.1 )]. WARNING: HYPONATREMIA See full prescribing information for complete boxed warning. Desmopressin acetate can cause hyponatremia, which may be life-threatening if severe. ( 5.1 ) Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids. ( 4 , 5.1 ) Ensure serum sodium concentration is normal before starting or resuming desmopressin acetate injection. Measure serum sodium within 1 week and approximately 1 month after starting therapy and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia. ( 2.1 , 5.1 ) If hyponatremia occurs, interrupt or discontinue desmopressin acetate injection. ( 5.1 )
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG The J. Molner Company LLC August 27, 2026
- Stimate HUMAN PRESCRIPTION DRUG Ferring Pharmaceuticals Inc. July 22, 2026
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Armas Pharmaceuticals Inc. June 22, 2026
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Armas Pharmaceuticals Inc. June 19, 2026
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG REMEDYREPACK INC. April 23, 2026
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Caplin Steriles Limited March 16, 2026
- DESMODA HUMAN PRESCRIPTION DRUG Eton Pharmaceuticals, Inc. March 2, 2026
- Desmopressin acetate HUMAN PRESCRIPTION DRUG Meitheal Pharmaceuticals Inc. January 23, 2026
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Northwind Health Company, LLC January 1, 2026
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG American Health Packaging November 13, 2025
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Bryant Ranch Prepack November 7, 2025
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Nordic Pharma, Inc. October 24, 2025
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Nordic Pharma, Inc. October 23, 2025
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Nordic Pharma, Inc. July 23, 2025
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Oceanside Pharmaceuticals June 19, 2025
- DESMOPRESSIN ACETATE HUMAN PRESCRIPTION DRUG UBI Pharma Inc. February 19, 2025
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Bryant Ranch Prepack January 31, 2025
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Nordic Pharma, Inc. December 6, 2024
- DESMOPRESSIN ACETATE HUMAN PRESCRIPTION DRUG UBI Pharma Inc. September 27, 2024
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Aurobindo Pharma Limited March 25, 2024
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG XGen Pharmaceuticals DJB, Inc. March 22, 2024
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG KVK-TECH, INC. February 21, 2024
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Fresenius Kabi USA, LLC September 6, 2023
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Fresenius Kabi USA, LLC September 6, 2023
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG BluePoint Laboratories August 4, 2023
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Gland Pharma Limited March 23, 2023
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Gland Pharma Limited November 18, 2022
- desmopressin acetate HUMAN PRESCRIPTION DRUG Sagent Pharmaceuticals October 12, 2022
- desmopressin acetate HUMAN PRESCRIPTION DRUG Sagent Pharmaceuticals October 12, 2022
- DDAVP HUMAN PRESCRIPTION DRUG Ferring Pharmaceuticals Inc. September 28, 2022
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Sun Pharmaceutical Industries, Inc. August 24, 2022
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Dr. Reddy's Laboratories Inc. July 26, 2022
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. March 30, 2022
- Desmopressin Acetate HUMAN PRESCRIPTION DRUG Bauch & Lomb Incorporated September 1, 2021
- DDAVP HUMAN PRESCRIPTION DRUG Ferring Pharmaceuticals Inc. February 3, 2021
- desmopressin acetate HUMAN PRESCRIPTION DRUG Sun Pharmaceutical Industries, Inc. January 23, 2020
- DESMOPRESSIN ACETATE HUMAN PRESCRIPTION DRUG Dr.Reddys' Laboratories Inc November 30, 2019
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.